ArticleDrug design, development and therapy2026
Outcomes and Safety of PD-1 Blockades Plus Anlotinib Regimen in Previously-Treated Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective, Exploratory Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective study was to identify the outcomes and safety of anlotinib combined with PD-1 blockades in patients with metastatic esophageal squamous cell carcinoma (ESCC). Methods: A retrospective analysis of 87 patients with histologically confirmed metastatic ESCC who received anlotinib plus PD-1 blockades as second-line or later therapy was performed. Efficacy endpoints included objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS). Safety was assessed by the incidence of treatment-related adverse events (TRAEs), graded in the principle of CTCAE v5.0. Results: Among 87 evaluable patients, no complete responses were observed, 19 subjects were partial response and 45 achieved stable disease, while 18 had disease progression and 5 were not evaluable for response. Therefore, ORR of the 87 subjects was 21.8% (95% CI: 13.7-32.0%), and DCR was 73.6% (95% CI: 63.0-82.4%). Median DoR of the 19 responders was 6.6 months [95% confidence interval (CI): 2.3-10.9 months]. Median PFS and OS for the cohort were 5.5 months (95% CI: 4.1-6.9 months) and 11.5 months (95% CI: 7.1-15.9), respectively, the 12-month and 24-month OS rates were 49.0% and 27.6%, respectively. Notably, patients with ESCC who had received prior immunotherapy showed better OS outcomes than those without prior immunotherapy exposure. Toxicity profile analysis demonstrated that the incidence of TRAEs with all grades was 92.0%. Grade ≥3 TRAEs occurred in 50.6% of the subjects. Common TRAEs included fatigue (60.9%), hypertension (52.9%), and nausea and vomiting (47.1%), most of which were grade 1-2 and manageable with supportive measures. Discussion: PD-1 blockades plus anlotinib demonstrated encouraging effectiveness and manageable toxicity in metastatic ESCC, achieving notable disease control and survival benefits compared with historical standards. Future prospective study is needed to confirm the therapeutic benefits and identify the optimal patient selection criteria for this promising combination therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.